The main challenge for an early-stage asset is to bridge the gap between initial research results and being an exploitable asset. Yet there are a variety of maturation models and initiatives, some of which combine public funding, technology transfer offices, the pharmaceutical industry and venture capital.  What are the current models for financing technology maturation? What are the different returns on investment of pre-venture capital tools? Which models currently work and which ones do not?

Moderator: Fausto Artico, Global R&D Tech Head and Director of Innovation and Data Science, GlaxoSmithKline